Illumina, Inc. (NASDAQ:ILMN) Stock Has Average Target Price of $219.69 According to Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have been assigned a consensus rating of “Hold” from the eighteen research firms that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $222.19.

A number of brokerages have recently issued reports on ILMN. Piper Sandler increased their price target on shares of Illumina from $225.00 to $305.00 and gave the company an “overweight” rating in a report on Monday, September 28th. Barclays boosted their price objective on shares of Illumina from $160.00 to $200.00 and gave the stock an “underweight” rating in a report on Wednesday. Sanford C. Bernstein restated a “market perform” rating and set a $215.00 target price on shares of Illumina in a research report on Friday, July 31st. TD Cowen increased their target price on shares of Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a report on Friday, July 31st. Finally, UBS Group upgraded shares of Illumina from a “neutral” rating to a “buy” rating and lifted their price target for the company from $135.00 to $260.00 in a research report on Wednesday, September 9th.

Illumina Stock Up 5.1%

Illumina stock opened at $278.17 on Wednesday. The stock’s 50 day moving average price is $227.18 and its 200 day moving average price is $180.89. Illumina has a 1-year low of $88.00 and a 1-year high of $309.35. The company has a market cap of $42.00 billion, a PE ratio of 51.90, a price-to-earnings-growth ratio of 3.75 and a beta of 1.41. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter in the prior year, the business posted $1.19 earnings per share. Illumina’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, sell-side analysts predict that Illumina will post 5.36 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Keith Meister sold 457,858 shares of Illumina stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the transaction, the director directly owned 2,372,694 shares of the company’s stock, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last ninety days, insiders sold 2,061,850 shares of company stock valued at $436,479,102. Company insiders own 2.90% of the company’s stock.

Institutional Trading of Illumina

Several large investors have recently bought and sold shares of ILMN. Fiduciary Financial Advisors purchased a new stake in Illumina in the 2nd quarter worth approximately $26,000. MCF Advisors LLC raised its holdings in Illumina by 172.4% in the 2nd quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 100 shares during the last quarter. Keating Financial Advisory Services Inc. purchased a new position in shares of Illumina during the 2nd quarter worth $32,000. Rakuten Securities Inc. purchased a new position in shares of Illumina during the 2nd quarter worth $33,000. Finally, Elevation Wealth Partners LLC boosted its holdings in shares of Illumina by 52.5% during the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock worth $43,000 after purchasing an additional 84 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.